17 October 2023
17 October 2023
There are currently many unmet needs for Parkinson’s patients but several pipeline drugs are looking to address these.
AbbVie announced Phase III head-to-head study data on the effectiveness of Skyrizi in Crohn’s disease.
Omeros pointed to an oversized placebo effect skewing comparison, adding that the results will not affect trials with narsoplimab in other indications.
Vidofludimus failed to meet the primary endpoint in the induction phase but showed clinical remission in the maintenance phase for ulcerative colitis.
The draft document provides sponsors with guidance on trial design, endpoints and entry criteria for diabetic foot infection trials.
The study will evaluate IntellexxDNA’s clinical decision support tool in creating a genomically targeted personalised plan for patients with early dementia.
The US government's Covid-19 research programme has announced the vaccine candidates for its latest round of funding.
The first patient cohort will receive 111MBq for each dose, while the second cohort will be given 185MBq.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
